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DEFINITIONS
Chronic obstructive pulmonary disease (COPD) includes the
conditions known as chronic bronchitis and emphysema. It is a
disease state resulting predominantly from smoking tobacco
and is characterised by airflow obstruction which is generally
progressive. It may be accompanied by hyperreactive airways,
and the airway obstruction may be partially reversible.
Chronic bronchitis refers to the presence of a chronic
productive cough for at least 3 months of the year in 2 or more
successive years in the absence of other recognised causes of
chronic cough.
Emphysema is a pathological diagnosis describing
permanent abnormal enlargement of the airspaces distal to the
terminal bronchioles, accompanied by destruction of alveolar
walls.
EPIDEMIOLOGY OF COPD
COPD is often diagnosed late because patients lack symptoms
in early stages of the disease despite the presence of moderate
decreases in pulmonary function. The primary risk factor for
COPD is dgarette smoking. However, in South Africa
tuberculosis and exposure to industrial and mining dust
probe bly constitute important additional causes of COPD.
Defidency of alpha-I-antitrypsin (alpha-I-protease inhibitor) is
a rare cause of disease. Patients with COPD have a more rapid
age-related decline in forced expiratory volume in 1 second
(FEY,) than normal subjects. This accelerated decline can be
slowed by smoking cessation. It is not clear whether recurrent
infectious exacerbations contribute to long-term worsening of
COPD. 0 reliable morbidity and mortality figures exist for
South Africa, but overseas studies have shown that mortality is
related to severity of disease. For example, an FEV, of < 35%
predicted carries a mortality of approximately 30% at 1 year.
• •
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AIMS OF THIS GUIDELINE
The purpose of this Guideline is to improve patient care at all
levels of the health system in South Africa (Table I), and it
contains an action plan for the recognition and appropriate
treatment of this common condition. It is not intended to be
prescriptive.
Table I. Goals of management
1. Recognition of disease (early diagnosis and staging)
2. Smoking cessation (secondary prevention)
3. Improvement of breathlessness (treatment of airflow
obstruction)
4. Pulmonary rehabilitation and education (improving quality
of life)
5. Prevention and treatment of complications and limitation of
disease progression
1. RECOGNITION OF DISEASE (EARLY
DIAGNOSIS AND STAGING)
Consider this diagnosis in the presence of chronic dyspnoea
and/or chronic cough with sputum production, and a long
history of smoking, usually more than 15 pack-years (1 pack-
year equals 20 cigarettes per day for one ye<l{).
To ensure that the correct treatment plan is followed, it is
important to differentiate asthma from COPD (Table IT).
Table IL Distinguishing features of COPD and asthma
Features suggesting COPD
• Persistent unremitting dyspnoea and productive cough
despite treatment
• A long history of smoking
• Slow progression




• Young age ot onset
• Presence of atopy and/or allergic rhinitis
• Diurnal and day-to-day variation and seasonal variability
• Marked improvement after bronchodilator and/or 2-week
trial of systemic steroids
Also note:
• Asthma and COPD may coexist, and distinguishing them
may be difficult
• Breathlessness occurs late in COPD
• Asthmatics who smoke may have an accelerated decline in
lung function
• Industrial exposure (e.g. to silica dust) and previous
tuberculosis may be associated with the development of
COPD
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1.1 Spirometry
Spirometry is essential for the detection, diagnosis, assessment
and management of patients with COPD and should be
performed by adequately trained persons using a spirometer of
the approved standard and calibrated regularly.
Peak expiratory flow rate measurements, while helpful in
asthma, are unsuitable for assessment of COPD.
Spirometric indices include the forced vital capacity (FVC)
and FEV1. Spirometry permits the following:
Detection of airflow obstruction
All patients with symptomatic COPD have airflow obstruction
with a reduced FEV!.
To diagnose airflow obstruction, the FEV! is expressed as a
percentage of the FVC. A value of less than 70% indicates
disease.
To assess the severity of airflow obstruction, FEV! is expressed
as a percentage of predicted values (in South Africa, predicted
values for the black population are 10% lower).
Absence of airflow obstruction should alert to the possibility
of an alternative diagnosis.
Assessment of degree of reversibility
Spirometry should be performed before and 20 minutes after
two puffs of a short-acting beta-2-agonist bronchodilator. An
improvement in FEV, of 15% and > 200 ml signifies a
significant reversible component and should alert to the
possibility of asthma.
Monitoring of a trial of systemic corticosteroids
For significant persistent breathlessness a trial of oral
corticosteroids is given (Table ill). This must be monitored with
spirometry (Table IV).
Table Ill. Corticosteroid trial
Indicated in the assessment of all stage IT and ill patients
May also be used to assess reversibility in stage I patients
• Prednisone 40 mg daily for 14 days
• Objective assessment of response must involve:
Detailed record of improvement in effort tolerance.
Spirometry:
Improvement of FEV, of > 15% and > 200 ml -
patient has a Significant reversible component. Treat as
for asthma
Improvement in FEY! by < 10% and significant
symptomatic improvement - if stage ill consider low-
dose oral steroids' and optimise bronchodilators
No objective response - optimise bronchodilators and
other supportive therapy, stop corticosteroids
• COllSider serious adverse effects of oral corticosteroids .
Assessment of the severity of disease
Spirometric staging is used to assess the severity of disease
(Table IV).
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Table IV. Spirometric staging of severity of COPD (performed while clinically stable)
FEYl (% pred) Symptoms Comments

























Patients with symptoms and corresponding spirometry compahole with stages IT and ill should preferably be referred for assessmeot by a pulmonologist.
Monitoring disease progression
COPD progresses slowly over years. More rapid deterioration















The chest radiograph on its own is not diagnostic, and a
normal chest radiograph does not exclude COPD. It is not
essential in all cases but may be useful for detecting additional
disease. The presence of bullae and/or scarring from previous
tuberculosis may indicate irreversible airway obstruction.
Mild effort related
dyspnoea









Increasing therapy for increasing severity
Fig. 1. Treatment guidelines for COPD (South African Pulmonology
Society Working Group),
2. SMOKING CESSATION (SECONDARY
PREVENTION)
e This is the only measure that slows progression of COPD.
e- Limited improvement occurs in many cases.
e Smoking cessation strategies must be implemented (see
supplementary note).
3. IMPROVEMENT OF BREATHLESSNESS
(TREATMENT OF AIRFLOW OBSTRUCTION)
For summary see Fig. 1.
3.1 Stage I
If the patient is breathless, treat with one of the following
bronchodilators (see supplementary nate).
Beta-Z-agonist metered dose inhaler (MDI)
(2 puffs approximately 6-hourly as needed)
or
Ipratropium MDI
(2 puffs approximately 6-hourly as needed)
or
Combination MDI of ipratropium
and beta-Z-agonist
(2 puffs approximately 6-hourly as needed)
or






2 puffs 6-hrly as needed
2 puffs 6-hrly as needed
2 puffs 6-hrly as needed
200 - 400 mg twice daily or 400 - 800 mg at night
Trial of steroids
40 mg prednisone for 14 days
Objective assessment of response




Treatment of aJr pulmonale
f'osstie nebJfiser therapy
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Regular oral SR theophylline
(200 - 400 mg twice daily or 400 - 800 mg at night).
3.2 Stage 11 and stage III
A trial of corticosteroids
A trial of corticosteroids forms part of the diagnostic
assessment and is an indicator of likely responsiveness to
therapy. It establishes a target lung function for bronchodilator
treatment and should be performed unless a medical
contraindication exists. Patients should be in a stable phase.
A short trial of corticosteroids will not reactivate tuberculosis.
When active tuberculosis is suspected and in cases where long-term
steroid therapy is planned, an initial chest radiograph is advised.
Bronchodilators
Regular beta-2-agonist and ipratropiurn MDI or equivalent
(usually 2 (up to 6 in severe cases) puffs approximately
6-hourly as needed)
with or without
Regular oral SR theophylline
(200 - 400 mg twice daily or 400 - 800 mg at night).
Long-term corticosteroids
Chronic oral corticosteroids improve symptoms and lung
function m: approximately 20% of patients, but because of side-
effects these should be used with caution. They should only be
used when objective evidence of improvement in stable
patients has been obtained. Regular attempts to reduce the
steroid dose should be made.
Although there is evidence of some airway inflammation in
COPD, the benefits of long-term preventive inhaled
corticosteroid treatment, recommended for asthma, have not
been confirmed. However, patients with a significant reversible
component who respond objectively to oral corticosteroids may
be given inhaled corticosteroids as a means of avoiding or
reducing the need for oral steroids.
Mucolytics and mucokinetic agents
Expectoration of tenacious sputum is a distressing symptom.
Unfortunately mucolytics, mucokinetic drugs, cough syrups
and acetylcysteine (oral and inhaled) have not been shown to
be effective and are not recommended.
Chest physiotherapy
An ineffective cough may be improved by instruction in the
'huff technique' of coughing and active cycle of breathing.
Percussion and vibration therapy do not form part of routine
management in stable patients.
The physiotherapist has an important role in directing the
conditioning (exercise) programme and in advising on
breathing and coughing techniques.
Other anti-asthma drugs
Other anti-asthma drugs, e.g. sodium cromoglycate, ketotifen
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and nedocromil soditun, are not useful in COPD.
Venesection
Increased haematocrit causes aggravation of cardiac failure,
increased ventilation/perfusion abnormality and an increased
incidence of thrombotic episodes. When the haematocrit is
> 0.55 consider repeated therapeutic venesection.
Other techniques
Bronchoscopy and pulmonary lavage has no role.
4. PULMONARY REHABILITATION AND
EDUCATION (IMPROVING QUALITY OF LIFE)
Rehabilitation programmes improve exercise tolerance and
quality of life. Rehabilitation involves a multidisciplinary
programme of physiotherapy, muscle training, nutritional
support, psychotherapy and education. Comprehensive
programmes are desirable and should be offered in specialised
centres.
4.1 Education
Education involves the following advice (preferably written):
• Benefits and techniques of smoking cessation
• Pathophysiology of disease
• Prognosis
• Drug treatment and side-effects of drugs
• Crisis plan for attacks of severe breathlessness or irtfection
- who to contact and how to cope
• Physiotherapy techniques
• Goals of exercise programmes
• Use of oxygen.
4.2 Physical conditioning
At a simple level patients should be given a graded
programme of upper and lower limb exercise, e.g. free-range
walking. Cycling and treadmill walking are useful alternatives.
More sophisticated programmes have limited benefit. Hypoxic
patients should be exercised with caution.
Breathing exercises, e.g. pursed lip breathing to improve
respiratory flows, 'diaphragmatic breathing' and relaxation
techniques, may be of benefit. Energy conservation measures
for the severely breathless include synchronised breathing,
avoidance of breath-holding, arm-support during activities
such as shaving, devices to aid towelling and bathing, etc.
4.3 Psychological support
This involves group and family support and advice to the
family from the practitioner and other care-givers.
4.4 Nutrition
Obesity and loss of body mass are both common features of
COPD. Obese patients should be advised to lose weight.
Under-nutrition is associated with respiratory muscle
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dysfunction and increased mortality. Weight gain in advanced
COPD is generally difficult to achieve. Simple advice to take
frequent small meals and not have large meals shortly before
retiring may improve nutrition and limit the dyspnoea
associated with eating.
5. PREVENTION AND TREATMENT OF
COMPLICATIONS AND LIMITATION OF DISEASE
PROGRESSION
5.1 Treatment of right ventricular failure
• Administer oxygen if hypoxaemic.
• Diuretics (e.g. hydrochlorothiazide 25 mg or equivalent).
Avoid large decreases in preload which may precipitate
hypotension.
• Cardiac glycosides are to be avoided except in the presence
of atrial fibrillation and/or left ventricular
dysfunction/failure.
• ACE inhibitors and calcium antagonists are not indicated in
cor pulmonale or right ventricular failure.
5.2 Infections in COPD
Prevention
Southern hemisphere influenza vaccination annually in March
is advised.
Treatment
In the presence of purulent sputum, a course of antibiotics such
as arnoxycillin, or one of the tetracycline derivatives (e.g.
doxycycline), is recommended for a minimum of 10 - 14 days.
Alternatives include new macrolide/azalide agents,
arnoxycillin/clavulanate and second-generation
cephalosporins. Quinolones may also be used as second-line
agents, especially in severely ill patients, particularly if guided
by sputum culture.
appropriate drug treatment before assessing hypoxaemia, as
blood gases may continue to improve for up to 3 months after
an acute exacerbation. Both arterial hypoxaemia and
spirometric values must be tested on two occasions at least 1
month and preferably 3 months apart before prescribing
LTDOT.
Continued smoking reduces the efficacy of treatment and is a
contraindication to oxygen therapy. Blood levels of
carboxyhaemoglobin above 3% suggest continued smoking.
Severe airflow obstruction (low FEV,) must be confirmed
since LTDOT is not of proven benefit in other forms of disease.
Oedema indicates cor pulmonale and a worse prognosis.
LTDOT has a significant benefit in this group.
In patients with hypercapnia, oxygen therapy must be
carefully controlled and arterial PaCO, should be assessed to
ensure that carbon dioxide retention does not occur.
Hypoxaemia is assessed with the patient at rest. Patients in
whom falls in PaO, occur only during exercise and sleep do not
benefit from LTDOT.
Other components of rehabilitation must be provided.
The patient (and family) must understand the nature and
goals of therapy and be aware that it is not intended for relief
of dyspnoea alone.
Regular follow-up by a suitably experienced physician and
ready access to technical advice, either through a private
contractor or a hospital department, must be available.
Assessment of compliance is essential.
The oxygen prescription. Oxygen is administered by
facemask or cannulae for a total of at least 15 hours during a
24-hour period. A flow rate of 1 - 2 l/min is used, the rate
being determined in each case by arterial blood gas (or
oximetry measurements after initial blood gas analysis)
determinations.
Oxygen can be delivered by oxygen concentrators or by
cylinders. Concentrators are more convenient and cost-
effective.
5.3 Treatment of hypoxaemia - oxygen therapy
Long-term domiciliary oxygen therapy (LTDOT)
This form of therapy, when given for the correct indications
with correction of hypoxaemia, results in reduction of
complications of respiratory failure and significant
improvement in survival of patients with chronic respiratory
failure.
Indications for LTDOT:
• Non-smokers with stable, severe chronic obstructive
I::liIim pulmonary disease (FEV, < 1.5 litres)
• Arterial hypoxaemia (partial arterial oxygen pressure (PaO,)
< 7.3 kPa or 55 mmHg)
• With or without hypercapnia (partial arterial carbon dioxide
pressure (PaCO,) > 6.0 kPa or 45 mmHg)
• With or without oedema.
The disease must be stable and patients must be on
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Palliative symptomatic oxygen therapy
When given for short periods to relieve breathlessness in
hypoxic patients, this does not influence the natural
progression of the disease and is therefore not routinely
recommended.
5.4 Evaluation and treatment of acute exacerbations
ofCOPD
Evaluation
Clinical assessment. Determine symptom changes from
baseline status, including sputum volume and character,
duration and progression of symptoms, dyspnoea severity,
exercise limitation and effect on activities of daily living.
Look for evidence of respiratory distress, bronchospasm, cor
pulmonale and right ventricular failure, pneumonia,
haemodynamic instability and altered mentation.
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Investigations. Arterial blood gas or pulse oximetry (if blood
gas is not available), chest radiograph, ECG and theophylline
level (if the patient has been on theophylline).
Treatment
Bronchodilators: (i) nebulisation with a combination of
ipratropium bromide and beta-2-agomst is usually indicated as
often as every 30 - 60 minutes in severe cases. Early conversion
to MDI is desirable. Alternatively multiple actuations of an
MDI with a spacer may be as effective; (ii) theophyllines -
should there be inadequate sustained response to the above
treatment, intravenous aminophylline may be used (Table V).
Table V. Theophylline guidelines
• Loading dose IV of 6 mg/kg if patient not on oral
theophylline
• Maintenance dose of 0.6 mg/kg/hour given as an infusion
• Blood. level monitoring and dose reduction if symptoms of
toxicity develop
• Reduce dose in elderly and those with cardiac failure
Anti-inflammatory therapy. Corticosteroids should be given,
preferably orally. A once-daily dose of 40 mg prednisone is
given and continued for 10 - 14 days unless the condition fails
to resolve. Tapering is not required.
An equivalent dose of an intravenous steroid may be given if
the patient is unable to take oral medication.
Antibiotics. These should be prescribed when there is
evidence of infection or increasing breathlessness considered to
be due to infection. Empiric antibiotic therapy is used and
includes oral amoxycillin, doxycycline or co-trimoxazole.
Alternatives such as amoxycillin/clavulanate, cefuroxime,
macrolides/azalides or quinolones may be used, particularly in
areas of high levels of resistant Haemophilus influenzae.
Intravenous administration is preferred for severe illness and
pneumonia on chest radiograph.
The duration of treatment should be 10 - 14 days for severely
ill patients or for persistent infections.
PosturaI drainage and chest percussion are of limited benefit
except in patients with excessive secretions.
Oxygen therapy. Oxygen should be started at 24% or 1 - 2
l/min by nasal cannulae. Increases should be gradual to avoid
carbon dioxide narcosis. This should be guided by blood gas
analysis or by level of consciousness if blood gases are not
available. The aim should be to maintain the saturation above
90%.
Treatment of cardiac failure. Right-sided cardiac failure is
treated primarily with oxygen and diuretics. As in chronic right
ventricular failure, there is no role for digoxin, calcium-channel
blockers or ACE inhibitors in acute right heart failure. It may
be necessary to use these agents if left ventricular failure
coexists.
Heparin prophylaxis. To prevent deep-vein thrombosis,
heparin should be given subcutaneously if there is no
contraindication.
Miscellaneous: (i) there is no place for oral or inhaled
mucolytics; (ii) coughing and forced expiratory manoeuvres aid
in the clearance of secretions. Instruction in correct breathing
patterns may relieve dyspnoea.
Indications for hospitalisation, ICD admission and
ventilatory support are summarised in Table VI.
6. ADDITIONAL CONSIDERATIONS
6.1 Sleep in COPD
Sleep is associated with a decrease in arterial oxygen saturation
(SaO,) in most individuals, but this trend is more marked in
COPD.
Significant night-time hypoxaemia cannot be predicted from
measurement of daytime blood gas and pulmonary function
tests, but if the daytime PaO, is ~ 8 kPa, nocturnal Sa02 need
only be measured if unexplained respiratory failure, cor
pulmonale or erythrocytosis is found.
Referral for a full sleep study (polysomnography) and
specialised opinion should only be considered in the setting of
suspected superimposed sleep-disordered breathing (i.e. in the
presence of daytime hypersornnolence and other symptoms of
sleep deprivation or a strong history of snoring or apnoeic
events).
Long-term domiciliary oxygen therapy, prescribed for
daytime hypoxaemia, must be used during sleep.
6.2 Surgery for emphysema
Giant bullectomy is occasionally indicated.
Lung volume reduction surgery (LVRS), bilateral non-
anatomical excision of emphysematous lung tissue, might be a
useful modality of therapy in an extremely small, highly
selected group of patients. These patients must be on optimal
medica_ therapy, severely symptomatic with dyspnoea, and
have evidence of marked air trapping without bullous disease.
The patient should be referred to a pulmonologist who is
participating in a multidisciplinary LVRS programme for
evaluation.
6.3 COPD and surgery
Patients with COPD are at higher risk during anaesthesia and
surgery. The risk depends on the severity of the lung disease
and the nature of the proposed surgery.
All patients require pre-operative evaluation, including
spirometry. For lung resection and upper abdominal and
thoracic surgery, the minimum evaluation should include
spirometry and arterial blood gas analysis.
Patients with continuous dyspnoea interfering with lifestyle
(stages II and ill) should undergo these investigations before
any anaesthetic.
The anaesthetic should be performed by someone
It
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Table VI. Indications for hospitalisation, lCU admission and ventilatory support in COPD
Hospitalisation lCU admission Ventilatory support
1. Acute exacerbation characterised by
increased dyspnoea, cough or sputum
production, plus one or more of the
following:
The usual indication for admission is
respiratory failure. However, it is
frequently necessary to admit patients
with other diseases because they have
COPD.
Patients with COPD often have
hypercapnia, hypoxaemia or severe
dyspnoea and these alone are not an
indication for ventilatory support.
·Sustained failure to improve on
outpatient management
• Inability to walk between rooms
(where previously mobile)
• Family and/or physician unable to
manage the patient at home.
• High-risk co-morbid condition,
pulmonary (e.g pneumonia) or non-
pulmonary
• Prolonged, progressive worsening of
symptoms before emergency visit
• Altered mentation
• Worsening hypoxaemia
• New or worsening hypercapnia
2 ew or worsening right-sided cardiac
failure unresponsive to outpatient
management.
Admission is subject to:'
1. Good functional ability prior to an
exacerbation if prior functional ability was
known (patient coped with activities of
daily living). If not known, the patient
should be given the benefit of the doubt.
2. Possible need for mechanical
ventilation, i.e.:
• PaOz < 6.7 kPa (SO mm Hg)
• pH < 7.3
• Confusion
3. The presence of a reversible element to
the disease. Examples would be:
infection, bronchospasm, oxygen-induced
carbon dioxide narcosis, sedative
administration or other associated
illnesses.
Specific indicators may be one or a
combination of (presuming the presence
of reversible factors):
1. Hypoxaemia (paOz < SO mm Hg)
despite supplemental oxygen
2. Exhaustion, confusion, coma
3. pH < 7.3 and declining (respiratory
acidosis)
4. Respiratory or cardiac arrest
5. Inability to clear secretions
Ventilatory support may consist of
invasive (mechanical ventilation) or non-
invasive (CPAP, BiPAP) techniques
Discharge plan
1. Education.
2. Consideration for domiciliary oxygen.
3. Provide written home management and treatment guideline.





experienced in dealing with the anaesthetic complications and
problems arising in these patients.
SUPPLEME TARY OTES
Smoking cessation
The important benefits of smoking cessation are that it reduces
the rate of decline of lung function to that of the normal ageing
process. Blood transport of oxygen improves. An initial small
increase in FEV, occurs in many patients. Although many
interventions show impressive short-term results, long-term
continued abstinence occurs in fewer than 30% of patients.
Factors associated with poor success include slow reductions in
cigarette consumption, multiple previous attempts to stop
smoking, heavy smoking, and relapse within the first 2 weeks.
Features of a successful programme include: (I) advice and
explanation by doctor and other caregivers/friends/farnily; (ii)
repeated reinforcement and follow-up; (iii) a variety of forms of
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psychotherapy which may involve group, individual or
behavioural methods; (iv) abrupt cessation (set quit date; 'cold
turkey'); and (v) nicotine gum or patches.
Minor benefit: clonidine, buspirone.
No benefit: hypnosis, acupuncture.
Avoidance of occupational and atmospheric pollution is
essential in alpha-I-antitrypsin deficiency.
Bronchodilators
Because a large proportion of COPD patients have a degree of
reversible airways obstruction, bronchodilators effect some
relief of symptoms and improved lung function occurs in most
cases. The magnitude of the effect is less than in asthma.
Bronchodilators do not alter the progressive decline in FEV,.
Beta-2-agonists (the inhaled route is preferred),
anticholinergics and theophyllines are effective. Individuals
vary in their responsiveness to each and combinations may




These agents have a rapid onset of action and achieve similar
effects to anticholinergics. They may be used regularly and as
monotherapy. Examples include salbutarnol, fenoterol,
terbutaline.
Anticholinergics
Anticholinergic agents have a slower onset of action (± 40
minutes to peak effects) but are effective for longer (6 hours),
improving symptoms, effort tolerance and airflow obstruction.
They are more effective than beta-2-agonists in many patients
and have fewer side-effects.
They do not reduce mucociliary clearance, or have significant
urinary or pupillary effects, even in high doses and in the
elderly. Ipratropiurn bromide is the only inhaled
anticholinergic currently available.
ebuliser treatment
This is an alternative for stage III patients with poor inhalation
technique and/or acute dyspnoea.
ebulised ipratropiurn plus beta-2-agonist can be used up
to 3 or more times daily.
• While there are distinct advantages, nebulisers tend to be
overused.
• Patients requiring nebuliser therapy should, where possible,
have specialist assessment.
Theophyllines
Theophyllines have similar or less bronchodilator effect than
beta-2-agonists but improve quality of life and have several
additional therapeutic advantages. The oral route of
administration is preferred by some patients and there is good
compliance with the sustained-release preparations.
Limitations are toxicity (particularly in the elderly), drug
interactions and variable metabolism.
Dosage: oral slow-release theophylline, 200 - 400 mg twice a
day or 400 - 800 mg at night. Recommended doses should not
be exceeded without monitoring blood levels.
A scheme for adjusting doses is as follows: (l) increase dose
by one-third - smokers and patients on phenytoin therapy;
(ii) decrease dose by one-third - patients with congestive
cardiac failure, the elderly, patients with liver disease and those
on most macrolide antibiotics, ciprofloxacin or cirnetidine.
Combination tablets containing theophylline and other
bronchodilators or sedatives are not recommended.
Long-acting beta-2-agonists
The use of long-acting beta-2-agonists in COPD is currently
being evaluated. They may be useful, but at present they do
not form part of routine management. A number of studies are
underway which should help clarify their role and indicate
which patients are most likely to benefit from their use. The
currently available long-acting beta-2-agonists are salmeterol
and formoterol.
Corticosteroids
Oral corticosteroids, used in the long term, may cause severe
side-effects. The decision to use oral maintenance steroids
should be made only if there is significant symptomatic and
objective evidence of beneficial effect. The dose should be
slowly reduced to the lowest that achieves adequate symptom
control. The use of alternate-day dosing may reduce side-
effects.
Patients should be monitored for common side-effects, which
include weight gain, impaired glucose tolerance, skin fragility,
hypertension and osteoporosis.
Inhaled corticosteroids may be used in steroid-responsive
patients in order to try to reduce the systemic dose.
Spacer devices and delivery methods
The use of spacer devices may improve delivery of medication
to the lower airways in patients with poor inhaler technique
and poor lung function.
Some patients may achieve better results with dry powder
devices. It is vital to ensure that the individual uses his inhaler
device correctly.
Air travel
The risks of air treatment include:
• Worsening hypoxaemia at altitude.
Most commercial aircraft are pressurised to an altitude of
between 7000 and 10 000 feet.
• Increased physical stress of travel (airport transfers,
luggage, etc.).
• Risk of contracting an intercurrent infection with
subsequent deterioration.
• Increased altitude at destination causing increased
dyspnoea.
Patients need to balance the potential discomforts and risks
with the intended objective of the trip.
The reed for supplemental oxygen can be predicted by
administering hypoxic air mixtures and measuring blood gases,
or by use of regression equations. However, a Simple approach
is recommended:
• Patients who are on LTDOT, or are hypoxaemic at sea level,
will need supplemental oxygen on the aircraft.
• Patients with limitation of activities of daily living should
make provision for supplemental oxygen with the airline
before the trip.
• Patients who have tolerated recent air travel well are likely
to cope with a similar trip.
• Coexistent disease, particularly ischaemic heart disease,
will make hypoxaemia more dangerous and more careful
as essment is necessary.
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A NEXURE A. METHODOLOGY OF THE
WORKING GROUP
The South African Pulmonology Society has long recognised
the need for a document to guide physicians and caregivers in
the assessment and management of the common disease,
chronic obstructive pulmonary disease. The Society has
experience in formulating guidelines, and employed the
following process.
A Working Group consisting of pulmonologists from seven
South African medical schools and from private practice, a
physiotherapist, a pharmacologist and an anaesthetist was
formed. Each university was invited to send an additional two
observers.
Prior to the first meeting of the Working Group the
participants were asked to prepare reviews of selected topics in
COPD, based on the relevant intemationalliterature. These
reviews were distributed to the participants before the meeting.
The Group met on the weekend of 16 March 1997. The
meeting was sponsored by Boehringer Ingelheim (Pty) Ltd.
Company representatives provided logistic support, but did
not take part in the discussions and were not involved in the
preparation of the guideline document.
Important general issues such as definitions and
classification of COPD were discussed in plenary sessions. The
reviews of selected topics were then discussed in small groups
in order to simplify and condense the document. The
recommendations of the small groups were reviewed in a
plenary session and the editorial committee was instructed to
prepare the draft document. This was performed by the four-
member editorial team by correspondence. A draft was
prepared and sent to all members of the Working Group. After
further comments on this draft were received, a second draft
was prepared and discussed in detail at a further meeting of
the Working Group held at the conference of the Pulmonology
Society in Windhoek in September 1997.
Discussions at this meeting led to further changes to the
document which was subsequently scrutinised and completed
by the editorial committee prior to submission to the Guideline
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